

## **Abstract**

### **Explaining the purpose of PGS/PGT-A**

**Nathan R. Treff PhD, HCLD(ABB)  
Chief Science Officer  
Genomic Prediction Inc**

**Aneuploidy is the most common genetic abnormality in humans. When applied correctly, preimplantation genetic testing for aneuploidy provides a clear benefit to patients undergoing treatment for infertility. Level I evidence from multiple randomized controlled trials demonstrate significantly increased success rates on the first attempted transfer and reduced risk of multiples. Research to better define patient populations which may benefit more than others is ongoing. This presentation will describe important considerations, such as requirements for embryology laboratory proficiency, the use of validated methodology, and the falsehoods surrounding mosaicism diagnoses.**